16 results about "Vimentin" patented technology

A method for the expression and / or for the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin. the method comprises applying to human skin at least one caviar extract which is capable of causing the expression and / or the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin.

The invention provides modRNA (Ribonucleic Acid) for treating obliterated bronchitis, and belongs to the technical field of bioengineering. The modRNA for treating obliterated bronchitis provided by the invention is composed of an IL-10 modRNA (Interleukin-10) and an IFN (Interferon)-alpha modRNA (Interferon-alpha) modRNA. The BO treatment effect is achieved by inhibiting bronchial epithelial cell epithelial-mesenchymal transition (EMT), the expression of alpha-SMA and Vimentin in lung tissue can be remarkably reduced, the expression of E-cadherin and Cytokeratin 5 can be up-regulated, microbronchial epithelial injury is repaired, collagen deposition is reduced, and the lung function is improved. The synergistic effect of the two is better than that of single gene therapy, the safety is high, and the controllability is strong.

The invention discloses application of METTL14 in inhibition of pituitary tumor cell proliferation and prognosis evaluation, and relates to the technical field of medicines. Experiments prove that when METTL14 is knocked out, E-cadherin can be lowered, and N-cadherin and waveform protein can be increased, so that the migration ability and proliferation and invasion ability of GH3 cells are promoted, and the tumor forming ability and in-vivo hormone level of pituitary growth hormone tumors are improved. Therefore, the METTL14 can be used for preparing a product for diagnosing or treating pituitary growth hormone adenoma, which is beneficial to theoretically researching pituitary adenoma and developing a novel targeted drug, and provides a new direction for finding a tumor marker or a new treatment strategy related to novel pituitary growth hormone adenoma diagnosis and controlling pituitary growth hormone adenoma.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a sperm-nourishing seed jade decoction and application thereof to improvement of endometrial receptivity, the sperm-nourishing seed jade decoction is composed of 30 g of radix rehmanniae preparata, 15 g of cornus officinalis, 15 g of radix paeoniae alba and 15 g of angelica sinensis, by inhibiting the epithelial-mesenchymal transition (EMT) process, the expression of E-cadherin and beta-catenin is up-regulated, the expression of Vimentin is down-regulated, and the endometrial receptivity is improved. Therefore, the stability and integrity of endometrial epithelium are maintained, intimal thickening, gland hyperplasia and angiogenesis are promoted, and an effective treatment strategy can be provided for infertility caused by thin endometrium.

The present application belongs to the technical field of tumor detection and cell separation, and particularly relates to a kit for separating and recovering after immunocapture of circulating tumor cells, a preparation method and application. The kit comprises an immunocapture module, a dissociation and recovery module, a cell protection module and elution and supplement factor solutions. The immunocapture module adopts magnetic microspheres modified by double antibody fusion proteins, can recognize multiple markers such as EpCAM and Vimentin, and realizes efficient capture of heterogeneous CTCs. The dissociation and recovery module uses a low-temperature buffer system and a cleavable cross-linking agent to release cells gently. The cell protection module maintains the integrity and activity of the cell membrane during the separation process. The method of the present application can ensure the capture efficiency while obtaining high-activity CTCs, and is suitable for single-cell sequencing, drug sensitivity analysis, organoid culture and patient-derived cell line construction and other preclinical research.

The invention discloses application of hAMSCs injected in different modes in preparation of drugs for improving pulmonary fibrosis EMT and apoptosis, and relates to the technical field of medicines. The hAMSCs provided by the invention are the third generation to the fifth generation of hAMSCs obtained by subculture, the hAMSCs highly express MSCs symbolic protein CD90, CD105, CD44 and CD73, and the hAMSCs lowly express CD11b, CD34, CD45 and CD19. The invention has proved that the expression of an epithelial marker E-cadherin can be increased by intratracheal or caudal vein injection of hAMSCs, and the expression of an interstitial marker vimentin is inhibited at the same time, so that the occurrence and development of IPF are prevented. A new thought is provided for preventing and preparing the IPF medicine.

This cell line is derived from a fish belonging to the family Anguillidae, expresses at least one selected from the group consisting of vimentin, CD29, CD73, and CD105, and has ability to accumulate fat. Also provided is a method for producing cells in which fat accumulates, the method involving a step for culturing the cell line derived from a fish belonging to the family Anguillidae in a culture medium, and causing fat to accumulate in the cells. Also provided is a fat production kit comprising the cell line derived from a fish belonging to the family Anguillidae, a fat accumulation culture medium, and a culture container.

This invention relates to the field of pharmaceutical technology, disclosing the application of a synthetic peptide that targets and inhibits GRP in the preparation of a drug for treating diabetic neuropathy. The synthetic peptide sequence is SWYLILRIENGKLVKEVVHVPD. This sequence targets and blocks the GRP / vimentin signaling axis. Vimentin is specifically expressed by astrocytes and is a characteristic protein of astrocyte activation. Astrocyte activation can cause central sensitization, leading to chronic pain and other chronic diseases. This synthetic peptide sequence is used in the preparation of a drug for treating diabetic neuropathy. This invention provides a GRP-targeting inhibitory peptide that has a good therapeutic effect on chronic pain, laying the foundation for clinical treatment of chronic pain and possessing significant application and promotion value.

The disclosure provides methods for identifying genomic loci (e.g., vimentin and / or SqBE18) that are differentially methylated in metaplasias (e.g., Barrett's esophagus) and / or neoplastic cancers (e.g., esophageal cancers). Identification of methylated genomic loci has numerous uses, including for example, to characterize disease risk, to predict responsiveness to therapy, to non-invasively diagnose subjects and to treat subjects determined to have gastrointestinal metaplasias and / or neoplasias.

The present invention relates to a STAT6 degrader and a composition for preventing or treating immune diseases, comprising same as an active ingredient. In the present invention, novel STAT6-PROTAC compounds capable of specifically degrading STAT6 were synthesized, and it was confirmed that the synthesized group of STAT6-PROTAC compounds specifically inhibited STAT6 in dermal fibroblasts. It was also confirmed that the STAT6-PROTAC compounds of the present invention inhibited fibrosis of skin and lung tissues in an animal model exhibiting increased systemic sclerosis disease activity induced by immune sensitization with vimentin. Furthermore, it was confirmed that the STAT6-PROTAC compounds ameliorate systemic sclerosis by inhibiting the expression of dermal fibrotic cytokines and fibrotic factors.

The application belongs to the technical field of fluorescence detection, and particularly relates to a multi-target circulating tumor cell quality control kit and a preparation method and application thereof. The kit comprises multi-marker quality control microspheres, a fixed storage system and a split packaging unit. The microspheres are 2-6 μm polymer base particles, and the surfaces of the microspheres are covalently coupled with recombinant antigen proteins such as EpCAM, CK8, Vimentin and CD45. Different microsphere subpopulations present various antigen combinations, and are used for simulating the marker characteristics of circulating tumor cells and immune cells. Through cross-linking fixation and freeze-drying protection treatment, the obtained quality control microspheres have good antigen stability and channel recognition performance, and are suitable for multi-platform quality control such as a flow cytometer and a multi-channel immunofluorescence system. The kit can replace traditional quality control cells, and realizes standardized, low-risk and long-term storage multi-target detection quality control.

The invention discloses application of chenodeoxycholic acid in preparation of drugs for promoting healing of diabetic wounds, and belongs to the technical field of medicines. The invention proves that CDCA can reverse fibroblast dysfunction induced by high glucose in a dose-dependent manner, remarkably improve cell proliferation and migration ability and repair expression of related genes (PCNA, alpha-SMA and Vimentin), and shows that CDCA has the characteristic of improving wound surface microenvironment by regulating and controlling multi-cell functions and has important clinical transformation value.

The invention discloses application of curculigoside in preparation of a medicine for preventing or treating renal fibrosis, and belongs to the technical field of biological medicine. In an in-vivo experiment, expression levels of Vimentin and alpha-SMA in kidney tissues of UUO model mice can be reduced through intraperitoneal injection of curculigoside, so that cell phenotypic transformation induced by TGF-beta1 is reduced, the collagenous fiber deposition area in Masson dyeing is reduced, the expression level of Collagen I protein in the kidney tissues of the UUO model mice is reduced, and the fibrosis process of the kidney tissues is reduced. Proved by signal generation analysis and cell thermal migration experiments, curculigoside can be combined with EZH2, which prompts that curculigoside can inhibit the fibrosis process through a targeted EZH2 pathway. It is proved for the first time that curculigoside has the effect of relieving renal fibrosis, and a new thought is provided for medicine development of curculigoside in the kidney disease direction.

The invention particularly relates to a human pneumosarcoma-like carcinoma organ as well as a construction method and application thereof, and belongs to the technical field of biological medicines. The organoid is selected from TJLCI-PSC-O-1 with the preservation number of CCTCC (China Center For Type Culture Collection) NO: C2025218 or TJLCI-PSC-O-2 with the preservation number of CCTCC NO: C2025334, or an amplified culture of an epithelial marker CK and a mesenchymal marker VIMENTIN which are stably co-expressed by the organoid. According to the construction method, a collagenase / dispersing enzyme and DNase I combined stepped enzymolysis system and a three-dimensional culture system are adopted, and high yield and long-term stable amplification of cells are realized. The model highly simulates the pulmonary sarcomatoid carcinoma pathological structure and epithelial-mesenchymal transition phenotype for the first time, can be used for in-vitro drug sensitivity test, in-vivo tumor formation model construction and drug screening, and provides a key platform for basic research and precise treatment of diseases.

Provided herein are containers comprising a composition comprising an antibody comprising a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:2. The containers can be bottles or vials, for example, glass or polyethylene terephthalate G (PETG) bottles or vials. Also provided are kits comprising the containers and methods of treating cancer using the antibodies from the containers.